Clinical trial · Interventional
Individualized Precision Treatment Based on Ovarian Cancer Organoid Model
Chief Physician of Obstetrics and Gynecology Department of the First Affiliated Hospital of Xiamen University
NCT05813509CI-TRIAL-00065679unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The research purpose of this study is to use organoid cultured from patients' own ovarian cancer tissues as models, screen potential clinical therapeutic drugs (such as paclitaxel, gemcitabine, etc.) in vitro, formulate individualized drug treatment plans for individual patient, and evaluate the clinical application value of organ like drug sensitivity technology.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Organoid culture | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Platinum resistant ovarian cancer
- description
- Advanced-stage epithelial ovarian cancer (stage III or above) that has received more than 2 lines of chemotherapy and recurred within 6 months after the chemotherapy is stopped;
- interventionNames
- Device: Organoid culture
Primary outcomes (1)
- measure
- Objective remission rate
- timeFrame
- 6 months
- description
- partial or complete remission ratio according to RECIST criteria
Secondary outcomes (1)
- measure
- Progression free survival
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion criteria 1. Patients diagnosed as primary nonmucous epithelial ovarian cancer with stage III or above by previous pathological diagnosis; 2. According to the relevant standards formulated by the World Health Organization (WHO) in 2014, measurable or assessable lesions are determined; 3. platinum-resistant epithelial ovarian cancer that has received more than 2 lines of chemotherapy; 4. There is no serious disease of important organs, and the patient can tolerate chemotherapy. Karnofsky score more than 60, and the expected survival period is more than half a year; 5. The liver, kidney and bone marrow functions were good. Exclusion criteria 1. Patients with other malignant tumors; 2. Patients with nervous system diseases; 3. Hepatitis B virus and human papilloma virus infection; 4. Immune function defect or serious infection; 5. Patients who cannot communicate effectively, disagree with the research requirements, and do not understand the research purpose.
References
Publications (0)
Data not yet available
No reference posted for this study.